Event puts Pitolisant program and stock in the spotlight

Harmony Biosciences Holdings (HRMY) is drawing fresh attention after six Pitolisant related abstracts were accepted for SLEEP 2026, along with reaffirmed revenue guidance and updated timelines for key regulatory and clinical milestones.

The recent Pitolisant updates and reaffirmed outlook come as the stock trades at US$34.46, with a 30 day share price return of 14.52% and a 1 year total shareholder return of 4.52%. This suggests momentum has picked up after a weaker year to date patch.

If you are weighing Harmony against other healthcare opportunities, this could be a good moment to see what else is on the move through the 40 healthcare AI stocks

With Harmony’s revenue and net income both growing on the latest annual figures and the stock trading at a discount to one widely followed price target and intrinsic value estimate, the key question is whether this is a genuine mispricing or if the market is already factoring in the company’s future pipeline potential.

Most Popular Narrative: 27.1% Undervalued

With Harmony Biosciences last closing at $34.46 against a most-followed fair value estimate of $47.30, the narrative frames the current valuation gap through the lens of growth, pipeline depth and legal risk around Wakix.

The large and growing patient populations affected by sleep disorders and rare neurodevelopmental conditions driven by demographic aging and increased recognition/diagnosis are expanding Harmony's total addressable market, supporting sustained long-term revenue growth for both existing and pipeline products.

Read the complete narrative. Read the complete narrative.

Curious what has to happen between now and 2028 for that fair value to hold up? Revenue expansion, margin improvement and a specific future earnings multiple sit at the core of this story, along with clear assumptions about how long Wakix cash flows can support the model.

Result: Fair Value of $47.30 (UNDERVALUED)

However, that story comes under pressure if legal outcomes shorten Wakix exclusivity or if late stage assets such as ZYN002 or EPX 100 fail to clear key regulatory hurdles.

Next Steps

If the mixed sentiment in this article leaves you undecided, review the numbers yourself and pressure test the optimism around Harmony's potential rewards through the 2 key rewards.

Looking for more investment ideas?

If Harmony has your attention, do not stop here. Give yourself options, compare opportunities side by side and let the data challenge your assumptions.

• Spot potential value candidates early by checking out the 44 high quality undervalued stocks.
• Prioritize resilience and sleep better at night by scanning the 71 resilient stocks with low risk scores.
• Hunt for lesser known stories with solid fundamentals by reviewing the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.